Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410663 | 0.86 | CASP7 (0.55) | KMT2AKDM4EMAPTGLAKDM1A | |
| SCHEMBL29211663 | 0.80 | DRD3 (0.46) | KDM1ARAB9ANPC1 | |
| SCHEMBL20475261 | 0.80 | MEN1 (0.58) | KMT2AKDM4EMAPTGLAPOLB | |
| SCHEMBL29566948 | 0.74 | MAOA (0.55) | KMT2AKDM4EMAPTPOLBMAOA | |
| SCHEMBL3343039 | 0.73 | POLB (0.52) | KMT2AKDM4EMAPTGLAKDM1A | |
| Benzene SCHEMBL27935642 | 0.69 | CYP3A4 (0.67) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL3349292 | 0.69 | POLB (0.61) | KMT2AKDM4EMAPTGLAKDM1A | |
| SCHEMBL29488275 | 0.69 | POLB (0.61) | KMT2AKDM4EMAPTGLAKDM1A | |
| SCHEMBL30481065 | 0.68 | — | — | |
| SCHEMBL19583344 | 0.68 | POLB (0.55) | KMT2AKDM4EMAPTGLAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286574-A | BLVRB enzyme function inhibitor and preparation method and application thereof | 吉林医药学院 | 2022-11-04 | — | — | CN | claimed |
| CN-115286574-B | BLVRB enzyme function inhibitor and preparation method and application thereof | 吉林医药学院 | 2023-07-11 | — | — | CN | disclosed |
| CN-115286574-A | BLVRB enzyme function inhibitor and preparation method and application thereof | 吉林医药学院 | 2022-11-04 | — | — | CN | disclosed |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-09-29 | — | — | US | disclosed |
| WO-2020248075-A9 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-10-21 | — | — | WO | disclosed |
| WO-2020248075-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-12-17 | — | — | WO | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | KMT2A 2669/4885KDM4E 2153/4885MAPT 1343/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | KMT2A 2583/4885KDM4E 2091/4885MAPT 1241/4885 |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | ERCC4, ERCC1, ERCC2 | KMT2A 4151/4885KDM4E 3255/4885MAPT 4637/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | KMT2A 2007/4885KDM4E 3418/4885MAPT 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.